3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Motor Activity
20
Polycystic Ovary Syndrome
10
Prostatic Neoplasms
7
Breast Neoplasms
6
Neoplasms
5
Colorectal Neoplasms
4
Insulin Resistance
3
Lung Neoplasms
2
Fatigue
2
Esophageal Neoplasms
2
Cardiotoxicity
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Primary Dysautonomias
1
Pediatric Brain Tumor
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lymphoma, Follicular
1
Lupus Erythematosus, Systemic
1
Inflammation
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Disease
1
Diabetes Mellitus, Type 1
1
Chemotherapy-Related Cognitive Impairment
1
Cardiovascular Diseases
1
Interventions
Gemcitabine
87
Cisplatin
66
Cystectomy
38
pembrolizumab
34
Docetaxel
25
Nivolumab
24
durvalumab
21
Paclitaxel
19
Magnetic Resonance Spectroscopy
18
Radiotherapy
17
Mitomycin
17
Carboplatin
16
atezolizumab
15
Doxorubicin
14
Cystoscopy
14
BCG Vaccine
13
Surveys and Questionnaires
12
Standard of Care
12
avelumab
11
Sunitinib
10
tremelimumab
9
Transurethral Resection of Bladder
9
Ipilimumab
9
Filgrastim
9
Blood Specimen Collection
9
Specimen Handling
8
Neoadjuvant Therapy
8
Methotrexate
8
Methods
8
Early Intervention, Educational
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Urinary Bladder Neoplasms
×
High-Intensity Interval Training
×
Clear all
NCT04593862
2024-09-19
BRAVE
University of Alberta
Phase 2
Completed
25 enrolled